Security
Elicio Therapeutics, Inc. Common Stock · ELTX
ELTXNASDAQCommon stockCurrentCIK 1601485Updated Oct 12, 2026
Name history
Angion Biomedica Corp. · through May 30, 2023
ELTX price & chart
Loading TradingView…
NASDAQ:ELTX on TradingView ↗About the company
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 7P was evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with mKRAS-positive pancreatic cancer who complet…
In the news
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX ↗
Recent filings
DEF 14A filing
Shareholder Director Nominations · Other Events
Items 5.08, 8.01
4 filing
4 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 28,284,000Source | 38,388,000Source | 31,330,000Source | 29,528,000Source | 15,750,000Source | 22,689,000Source | 28,144,000Source | 24,480,000Source | 25,862,000Source | 28,178,000Source | 27,146,000Source | 52,790,000Source |
| Property, Plant and Equipment, NetUSD | 328,000Source | 523,000Source | 213,000Source | 377,000Source | 597,000Source | 249,000Source | 430,000Source | 635,000Source | 295,000Source | 483,000Source | 717,000Source | 273,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,611,000Source | 26,016,000Source | 23,480,000Source | 22,088,000Source | 3,425,000Source | 14,948,000Source | 18,351,000Source | 11,853,000Source | 18,563,000Source | 17,618,000Source | 12,894,000Source | 50,487,000Source |
| Assets, CurrentUSD | 21,465,000Source | 30,646,000Source | 25,485,000Source | 22,598,000Source | 6,689,000Source | 16,200,000Source | 20,935,000Source | 14,130,000Source | 19,311,000Source | 20,693,000Source | 16,348,000Source | 51,430,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 854,000Source | 3,312,000Source | 2,005,000Source | 510,000Source | 2,868,000Source | 1,252,000Source | 1,901,000Source | 1,612,000Source | 748,000Source | 1,897,000Source | 2,732,000Source | 943,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,019,000Source | 5,926,000Source | 4,292,000Source | 5,253,000Source | 6,142,000Source | 4,539,000Source | 5,481,000Source | 6,354,000Source | 4,782,000Source | 5,706,000Source | 6,563,000Source | 152,000Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 61,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 24,468,000Source | 57,374,000Source | 23,393,000Source | 27,694,000Source | 17,402,000Source | 24,126,000Source | 19,240,000Source | 19,610,000Source | 24,226,000Source | 39,490,000Source | 15,773,000Source | 9,018,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | — | — | 0Source | — | — | 0Source | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 173,000Source | 108,000Source | 219,000Source | 163,000Source | 103,000Source | 186,000Source | 160,000Source | 102,000Source | 178,000Source | 110,000Source | 96,000Source | 301,000Source |
| Additional Paid in CapitalUSD | 229,778,000Source | 161,355,000Source | 261,706,000Source | 217,762,000Source | 159,892,000Source | 244,144,000Source | 214,348,000Source | 159,218,000Source | 235,407,000Source | 183,004,000Source | 153,827,000Source | 297,327,000Source |
| Retained Earnings (Accumulated Deficit)USD | -225,954,000Source | -180,097,000Source | -253,712,000Source | -215,871,000Source | -161,259,000Source | -245,495,000Source | -205,310,000Source | -154,030,000Source | -233,672,000Source | -194,101,000Source | -142,203,000Source | -253,942,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -31,000Source | -202,000Source | -126,000Source | -70,000Source | -238,000Source | -122,000Source | -144,000Source | -270,000Source | -127,000Source | -175,000Source | -197,000Source | 86,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,816,000Source | -18,986,000Source | 7,937,000Source | 1,834,000Source | -1,652,000Source | -1,437,000Source | 8,904,000Source | 4,870,000Source | 1,636,000Source | -11,312,000Source | 11,373,000Source | 43,772,000Source |
| Liabilities and EquityUSD | 28,284,000Source | 38,388,000Source | 31,330,000Source | 29,528,000Source | 15,750,000Source | 22,689,000Source | 28,144,000Source | 24,480,000Source | 25,862,000Source | 28,178,000Source | 27,146,000Source | 52,790,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,515,000Source | 9,020,000Source | 9,202,000Source | 9,923,000Source | 7,585,000Source | 7,229,000Source | 11,413,000Source | 5,951,000Source | 8,110,000Source | 11,523,000Source | 9,766,000Source | 6,369,000Source |
| Operating Lease, Liability, CurrentUSD | 981,000Source | 877,000Source | 1,073,000Source | 952,000Source | 854,000Source | 1,042,000Source | 926,000Source | 881,000Source | 1,011,000Source | 901,000Source | 910,000Source | 994,000Source |
| Accounts Payable, CurrentUSD | 321,000Source | 1,984,000Source | 839,000Source | 3,865,000Source | 1,055,000Source | 272,000Source | 4,037,000Source | 1,105,000Source | 672,000Source | 1,038,000Source | 4,369,000Source | 2,720,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,356,000Source | 5,338,000Source | 3,540,000Source | 4,613,000Source | 5,565,000Source | 3,823,000Source | 4,865,000Source | 5,791,000Source | 4,094,000Source | 5,105,000Source | 6,007,000Source | 2,481,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,213,000Source | 4,852,000Source | 7,290,000Source | 5,106,000Source | 5,321,000Source | 5,915,000Source | 5,770,000Source | 3,324,000Source | 6,427,000Source | 8,415,000Source | 3,757,000Source | 2,569,000Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | 10,000,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 9,720,000Source | — | 9,535,000Source | 9,337,000Source | — | 9,475,000Source | — | — | 9,407,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 868,000Source | 517,000Source | 2,697,000Source | 1,452,000Source | 1,179,000Source | 885,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -460,000Source | 2,999,000Source | -366,000Source | -3,331,000Source | 23,000Source | -2,050,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -11,645,000Source | -10,119,000Source | -36,952,000Source | -37,068,000Source | -32,694,000Source | -38,390,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | -16,000Source | -84,000Source | -32,000Source | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 16,000Source | 87,000Source | 66,000Source | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 8,027,000Source | 10,328,000Source | 36,695,000Source | 42,321,000Source | 38,613,000Source | -60,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,613,000Source | 240,000Source | -225,000Source | 5,191,000Source | 5,887,000Source | -38,269,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 21,313,000Source | 28,027,000Source | 23,995,000Source | 22,788,000Source | 15,654,000Source | 19,732,000Source | 19,267,000Source | 19,492,000Source | 14,301,000Source | 50,487,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 5,000Source | 31,000Source | 48,000Source | 22,000Source | 0Source | 181,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 698,000Source | 314,000Source | 935,000Source | 710,000Source | 868,000Source | 517,000Source | 2,697,000Source | 1,452,000Source | 1,179,000Source | 885,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | 300,000Source | 300,000Source | — | — | 0Source |
| DepreciationUSD | — | — | 100,000Source | 0Source | 100,000Source | 100,000Source | 46,000Source | 53,000Source | 204,000Source | 321,000Source | 382,000Source | 178,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | — | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 3,000Source | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -1,000Source | 1,000Source | 0Source | 13,000Source | 0Source | 0Source | 151,000Source | 204,000Source | -237,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | 3,000Source | -105,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 605,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,006,000Source | 3,136,000Source | 3,618,000Source | 3,085,000Source | 3,845,000Source | 2,958,000Source | 12,811,000Source | 11,330,000Source | 11,896,000Source | 14,637,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 151,000Source |
| Income (Loss) from Equity Method Investments, Net of Dividends or DistributionsUSD | — | — | — | — | — | — | — | — | — | — | — | 151,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 11,000Source |
| InterestExpenseNonoperatingUSD | — | — | 426,000Source | 137,000Source | 410,000Source | 194,000Source | 407,000Source | 176,000Source | 1,133,000Source | 455,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,083,000Source | -18,838,000Source | -8,217,000Source | -10,561,000Source | -11,823,000Source | -11,209,000Source | -39,571,000Source | -51,898,000Source | -35,195,000Source | -38,807,000Source |
| Nonoperating Income (Expense)USD | — | — | -2,038,000Source | -8,494,000Source | 2,212,000Source | -470,000Source | -1,221,000Source | -473,000Source | -1,857,000Source | -6,912,000Source | 550,000Source | 814,000Source |
| Operating Lease, ExpenseUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 700,000Source | 300,000Source | 300,000Source | 1,400,000Source | 1,500,000Source | 1,500,000Source | — |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 3,021,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 835,000Source | 16,244,000Source | 4,555,000Source | 6,999,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 100,000Source | 7,000Source | 149,000Source | 39,000Source | 127,000Source | 0Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 2,301,000Source |
| Investment Income, Interest | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 2,301,000Source |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -8,045,000Source | -10,344,000Source | -10,429,000Source | -10,091,000Source | -10,602,000Source | -10,736,000Source | -37,714,000Source | -44,986,000Source | -35,745,000Source | -39,621,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -39,571,000Source | — | — | -38,798,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 11,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,083,000Source | -18,838,000Source | -8,217,000Source | -10,561,000Source | -11,823,000Source | -11,209,000Source | -39,571,000Source | -51,898,000Source | -35,195,000Source | -38,807,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.6Source | -1.39Source | -0.43Source | -0.66Source | -0.65Source | -0.87Source | -2.58Source | -4.25Source | -6.96Source | -1.29Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.6Source | -1.39Source | -0.43Source | -0.66Source | -0.65Source | -0.87Source | -2.58Source | -4.25Source | -6.96Source | -1.29Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 16,692,476Source | 13,582,345Source | 19,244,679Source | 16,059,423Source | 18,211,745Source | 12,950,574Source | 15,312,751Source | 12,202,996Source | 5,056,225Source | 30,040,703Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 16,692,476Source | 13,582,345Source | 19,244,679Source | 16,059,423Source | 18,211,745Source | 12,950,574Source | 15,312,751Source | 12,202,996Source | 5,056,225Source | 30,040,703Source |
| Interest Expense (non-operating)USD | — | — | 426,000Source | 137,000Source | 410,000Source | 194,000Source | 407,000Source | 176,000Source | 1,133,000Source | 455,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 8,045,000Source | 10,344,000Source | 10,429,000Source | 10,091,000Source | 10,602,000Source | 10,736,000Source | 37,714,000Source | 44,986,000Source | 35,745,000Source | 41,922,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 11,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -1,000Source | 1,000Source | 0Source | 13,000Source | 0Source | 0Source | 151,000Source | 204,000Source | -237,000Source |
| General and Administrative ExpenseUSD | — | — | 3,006,000Source | 3,136,000Source | 3,618,000Source | 3,085,000Source | 3,845,000Source | 2,958,000Source | 12,811,000Source | 11,330,000Source | 11,896,000Source | 14,637,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -39,476,000Source | — | — | -38,302,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 151,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,059,000Source | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 805,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | 373,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -2,038,000Source | -8,494,000Source | 2,212,000Source | -470,000Source | -1,221,000Source | -473,000Source | -1,857,000Source | -6,912,000Source | 550,000Source | 814,000Source |
| Operating Lease, ExpenseUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 700,000Source | 300,000Source | 300,000Source | 1,400,000Source | 1,500,000Source | 1,500,000Source | — |
| Research and Development ExpenseUSD | — | — | 5,039,000Source | 7,208,000Source | 6,811,000Source | 7,006,000Source | 6,757,000Source | 7,778,000Source | 24,903,000Source | 33,656,000Source | 23,849,000Source | 18,100,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 2,301,000Source |
| Investment Income, Interest | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-293861
Filing attachments
tm2619637d1_ex99-1.htm · 8-K · 2026-07-02
EX-99.1 5 tm2619637d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering BOSTON, July 01, 2026 - Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation …
Read attachment ↗d38971dex991.htm · 8-K · 2025-09-17
EX-99.1 2 d38971dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapy Robust mKRAS-specific T cell responses were observed with an average of 145.3x increase over baseline (median 44.3x; range …
Read attachment ↗d38971dex992.htm · 8-K · 2025-09-17
EX-99.2 3 d38971dex992.htm EX-99.2 EX-99.2 September 2025 AMPLIFY-7P Phase 2 Immunogenicity Data Nasdaq: ELTX Exhibit 99.2 Disclaimers No Representation or Warranty We do not make and hereby expressly disclaim any representation or warranty, express or implied, as to the reasonableness of the assumptions made in the Presentation or the accuracy or completeness or the information contained in or incorporated by reference into the Presentation. We will not have any liability for any represen…
Read attachment ↗d914999dex41.htm · 8-K · 2025-01-30
EX-4.1 2 d914999dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 ELICIO THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Warrant No.: ___ Number of Shares of Common Stock: ____________ Date of Issuance: January 30, 2025 (“Issuance Date”) Elicio Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ________, the registered holder hereof or its permitted assigns …
Read attachment ↗d914999dex991.htm · 8-K · 2025-01-30
EX-99.1 5 d914999dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules BOSTON, January 30, 2025 - Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered into definitive securities purchase agreements with institutional inve…
Read attachment ↗